Intervet readies expansion plans

MILLSBORO, DEL.—Intervet Inc. formed a new Companion Animal Business Team to expand its presence in the U.S. companion animal market segment.

This decision was driven by the necessity to have a specialized companion animal team to better support the evolving needs of both the veterinary profession and pet owners, the company reports.

Intervet is expanding its presence in the companion animal market through the introduction of vaccines and pharmaceuticals.

The recent regulatory approval of Vetsulin(tm) (porcine insulin zinc suspension), the first and only veterinary-use insulin approved by the U.S. Food and Drug Administration for the treatment of diabetes mellitus in dogs, is the first of several new products expected from an intensive research and development effort initiated in the mid-1990's intended to expand Intervet's offering and commitment to the companion animal veterinary community.

Dr. Sebastien Huron, director of the Companion Animal Business Team, explains: "By having a focused team of professional sales, marketing and technical services representatives, Intervet is underscoring the importance of better serving the U.S. companion animal veterinarians. Intervet's worldwide leadership and focused research and development initiatives provide a solid foundation for the delivery of new technologies designed to answer a variety of unmet medical needs of our pets."

Intervet will be present at all major conventions next year, beginning with the North American Veterinary Conference in Orlando in January 2005, and will offer product information and technical support to veterinarians and pet owners.

For fastest response, call

(302) 934-4448

www.intervetusa.com